How do enzymatic synthesis platforms compare with phosphoramidite chemistry on per-base cost?

Enzymatic platforms currently run 2–3× higher per base than phosphoramidite for short oligos under 60-mers, but the cost gap narrows sharply for sequences above 150-mers, where chemical coupling efficiency drops [5]. Volume production and next-generation enzyme engineering should bring enzymatic costs to parity by 2029. Read More

What quality certifications should buyers require from an oligo CDMO?

Buyers should insist on ISO 13485 for diagnostic-grade and FDA 21 CFR Part 211 compliance for therapeutic-grade custom oligo manufacturing [17]. Third-party audit reports and batch-level certificate of analysis documentation are essential procurement safeguards. Read More

Which antisense oligonucleotide therapy indications offer the largest near-term synthesis volume?

Spinal muscular atrophy and hereditary transthyretin amyloidosis programs drive the bulk of current GMP oligo demand, collectively consuming an estimated 400+ kilograms annually [8]. Cardiometabolic indications entering Phase III will add significant volume by 2028. Read More

How does the CRISPR guide RNA production scale differ from standard research oligo orders?

CRISPR screening campaigns require 10,000–100,000 unique guide sequences per project, each at microgram scale, making pooled array-based nucleic acid chemistry synthesis the preferred method [7]. Clinical candidates then shift to single-sequence GMP production at the gram scale. Read More

What procurement strategies reduce lead-time risk in the Oligonucleotide Synthesis Market?

Dual-sourcing across geographies — pairing a North American CDMO with an Asia-Pacific provider — hedges against single-point disruptions [6]. Framework agreements with guaranteed capacity reservations reduce lead times from 8–12 weeks to under 4 weeks. Read More

How are environmental regulations reshaping the Oligonucleotide Synthesis Market supply chain?

The EU's expanded REACH restrictions on PFAS and acetonitrile waste are forcing CDMOs to invest in solvent-recovery systems or pivot to enzymatic DNA/RNA strand production methods [10]. Facilities that cannot demonstrate green chemistry compliance risk losing European procurement contracts. Read More

What role does AI play in reducing nucleic acid chemistry synthesis error rates?

Machine-learning models now predict coupling failure hotspots and optimize cycle parameters in real time, cutting truncation errors by up to 30% on sequences above 100-mers [21]. These AI tools also accelerate CRISPR guide RNA production design by screening millions of candidate sequences in hours. Read More

Oligonucleotide Synthesis Market

ID: MRFR/LS/1721-HCR

200 Pages

Satyendra Maurya

Last Updated: June 22, 2026

Oligonucleotide Synthesis Market Research Report: Size, Share, Trend Analysis By Product Type (DNA Oligonucleotides, RNA Oligonucleotides, Modified Oligonucleotides, ASO Oligonucleotides), By Applications (Diagnostics, Therapeutics, Research Development, Gene Synthesis), By End Users (Pharmaceutical Companies, Biotechnology Companies, Academic Research Institutions, Contract Research Organizations), By Technology (Solid-Phase Synthesis, Liquid-Phase Synthesis, Microarray Technology) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Methodology Download PDF

Certified Researchers

Customize Report

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Takeaways
3 Market Dynamics |
1. 3.1 Market Drivers Analysis | |
  1. 3.1.1 Expanding Nucleic Acid Therapeutics Pipeline | |
  2. 3.1.2 Enzymatic Synthesis Platform Adoption | |
  3. 3.1.3 CRISPR Guide RNA Production Demand | |
  4. 3.1.4 Government Research Funding Programs | |
  5. 3.1.5 Pharmaceutical Outsourcing to CDMOs | |
  6. 3.1.6 Molecular Diagnostics Expansion | |
  7. 3.1.7 Environmental Regulation of Legacy Reagents |
2. 3.2 Market Restraints Analysis | |
  1. 3.2.1 High Cost of GMP-Grade Custom Oligo Manufacturing | |
  2. 3.2.2 Intellectual Property Barriers Around Modified Nucleotides | |
  3. 3.2.3 Quality Consistency at Kilogram Scale | |
  4. 3.2.4 Skilled Workforce Shortages in Oligo Chemistry | |
  5. 3.2.5 Regulatory Uncertainty for Novel Modifications |
3. 3.3 Market Opportunity Analysis | |
  1. 3.3.1 Enzymatic Synthesis Disruption for Point-of-Care Applications | |
  2. 3.3.2 Asia-Pacific Capacity Buildout | |
  3. 3.3.3 Data Monetization Through Synthesis-as-a-Service Platforms | |
  4. 3.3.4 mRNA Vaccine and Therapeutic Expansion | |
  5. 3.3.5 Sustainable Chemistry and Green Synthesis |
4. 3.4 Industry Value Chain Analysis |
5. 3.5 Porter's Five Forces Analysis
4 Global Oligonucleotide Synthesis Market Size & Forecast (2021–2035) |
1. 4.1 Historical Market Size (2021–2025) |
2. 4.2 Current & Forecast Market Size (2026–2035) |
3. 4.3 Market Size by Revenue (USD Billion) |
4. 4.4 Year-over-Year Growth Analysis
5 Segmentation Analysis |
1. 5.1 By Product Type | |
  1. 5.1.1 Services | |
  2. 5.1.2 Synthesized Oligonucleotide Products | |
  3. 5.1.3 Reagents & Consumables |
2. 5.2 By Chemistry | |
  1. 5.2.1 DNA | |
  2. 5.2.2 RNA | |
  3. 5.2.3 Modified Chemistries (LNA, PNA, etc.) |
3. 5.3 By Application | |
  1. 5.3.1 Research | |
  2. 5.3.2 Therapeutics | |
  3. 5.3.3 Diagnostics |
4. 5.4 By End-User | |
  1. 5.4.1 Academic Research Institutes | |
  2. 5.4.2 Pharmaceutical & Biotechnology Companies | |
  3. 5.4.3 Diagnostic Companies
6 Regional Analysis |
1. 6.1 North America | |
  1. 6.1.1 United States | |
  2. 6.1.2 Canada | |
  3. 6.1.3 Mexico |
2. 6.2 Europe | |
  1. 6.2.1 Germany | |
  2. 6.2.2 United Kingdom | |
  3. 6.2.3 France | |
  4. 6.2.4 Italy | |
  5. 6.2.5 Spain | |
  6. 6.2.6 Nordic Countries | |
  7. 6.2.7 Russia | |
  8. 6.2.8 Rest of Europe |
3. 6.3 Asia-Pacific | |
  1. 6.3.1 China | |
  2. 6.3.2 India | |
  3. 6.3.3 Japan | |
  4. 6.3.4 South Korea | |
  5. 6.3.5 ASEAN | |
  6. 6.3.6 Rest of Asia-Pacific |
4. 6.4 South America | |
  1. 6.4.1 Brazil | |
  2. 6.4.2 Argentina | |
  3. 6.4.3 Rest of South America |
5. 6.5 Middle East & Africa | |
  1. 6.5.1 Saudi Arabia | |
  2. 6.5.2 UAE | |
  3. 6.5.3 South Africa | |
  4. 6.5.4 Egypt | |
  5. 6.5.5 Rest of MEA
7 Competitive Landscape |
1. 7.1 Market Share Analysis (2025) |
2. 7.2 Competitive Benchmarking Matrix |
3. 7.3 Company Profiles | |
  1. 7.3.1 Thermo Fisher Scientific | |
  2. 7.3.2 Agilent Technologies | |
  3. 7.3.3 Integrated DNA Technologies (IDT) | |
  4. 7.3.4 Eurofins Genomics | |
  5. 7.3.5 GenScript Biotech | |
  6. 7.3.6 LGC Biosearch Technologies | |
  7. 7.3.7 Twist Bioscience | |
  8. 7.3.8 Ajinomoto Bio-Pharma | |
  9. 7.3.9 Bio-Synthesis Inc. | |
  10. 7.3.10 Nitto Denko Avecia
8 Future Outlook & Strategic Recommendations (2026–2035) |
1. 8.1 AI-Accelerated Sequence Design and Synthesis Optimization |
2. 8.2 Platform Economics and Synthesis-as-a-Service |
3. 8.3 Therapeutic Oligonucleotide Industrialization |
4. 8.4 ESG-Driven Green Chemistry Transition
9 Recent Developments & News
10 Frequently Asked Questions (FAQs)
11 Report Scope & Methodology |
1. 11.1 Study Period & Base Year |
2. 11.2 Data Sources & Citations |
3. 11.3 Abbreviations
12 LIST OF TABLES |
TABLE 1 Global Oligonucleotide Synthesis Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global Oligonucleotide Synthesis Market – Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Global Oligonucleotide Synthesis Market – Driver Impact Analysis |
TABLE 4 Global Oligonucleotide Synthesis Market – Restraint Impact Analysis |
TABLE 5 Global Oligonucleotide Synthesis Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 6 Global Oligonucleotide Synthesis Market Size, by Chemistry, 2021–2035 (USD Billion) |
TABLE 7 Global Oligonucleotide Synthesis Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 8 Global Oligonucleotide Synthesis Market Size, by End-User, 2021–2035 (USD Billion) |
TABLE 9 Global Oligonucleotide Synthesis Market Size, by Region, 2021–2035 (USD Billion) |
TABLE 10 North America Oligonucleotide Synthesis Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 11 Europe Oligonucleotide Synthesis Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 12 Asia-Pacific Oligonucleotide Synthesis Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 13 South America Oligonucleotide Synthesis Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 14 Middle East & Africa Oligonucleotide Synthesis Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 15 Competitive Benchmarking Matrix – Global Oligonucleotide Synthesis Market, 2025 |
TABLE 16 Company Profiles – Key Players, Global Oligonucleotide Synthesis Market |
TABLE 17 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 18 North America Oligonucleotide Synthesis Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 19 North America Oligonucleotide Synthesis Market Size, by Chemistry, 2021–2035 (USD Billion) |
TABLE 20 North America Oligonucleotide Synthesis Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 21 North America Oligonucleotide Synthesis Market Size, by End-User, 2021–2035 (USD Billion) |
TABLE 22 Europe Oligonucleotide Synthesis Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 23 Europe Oligonucleotide Synthesis Market Size, by Chemistry, 2021–2035 (USD Billion) |
TABLE 24 Europe Oligonucleotide Synthesis Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 25 Europe Oligonucleotide Synthesis Market Size, by End-User, 2021–2035 (USD Billion) |
TABLE 26 Asia-Pacific Oligonucleotide Synthesis Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 27 Asia-Pacific Oligonucleotide Synthesis Market Size, by Chemistry, 2021–2035 (USD Billion) |
TABLE 28 Asia-Pacific Oligonucleotide Synthesis Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 29 Asia-Pacific Oligonucleotide Synthesis Market Size, by End-User, 2021–2035 (USD Billion) |
TABLE 30 South America Oligonucleotide Synthesis Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 31 South America Oligonucleotide Synthesis Market Size, by Chemistry, 2021–2035 (USD Billion) |
TABLE 32 South America Oligonucleotide Synthesis Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 33 South America Oligonucleotide Synthesis Market Size, by End-User, 2021–2035 (USD Billion) |
TABLE 34 Middle East & Africa Oligonucleotide Synthesis Market Size, by Product Type, 2021–2035 (USD Billion) |
TABLE 35 Middle East & Africa Oligonucleotide Synthesis Market Size, by Chemistry, 2021–2035 (USD Billion) |
TABLE 36 Middle East & Africa Oligonucleotide Synthesis Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 37 Middle East & Africa Oligonucleotide Synthesis Market Size, by End-User, 2021–2035 (USD Billion) |
TABLE 38 Report Scope & Methodology Summary |
TABLE 39 Detailed Sources and Citations
13 LIST OF FIGURES |
FIGURE 1 Global Oligonucleotide Synthesis Market Dynamics (Drivers, Restraints, Opportunities) |
FIGURE 2 Industry Value Chain Analysis — Oligonucleotide Synthesis Market |
FIGURE 3 Porter's Five Forces Analysis — Oligonucleotide Synthesis Market |
FIGURE 4 Global Oligonucleotide Synthesis Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 5 Global Oligonucleotide Synthesis Market Share, by Product Type, 2025 (%) |
FIGURE 6 Global Oligonucleotide Synthesis Market Share, by Chemistry, 2025 (%) |
FIGURE 7 Global Oligonucleotide Synthesis Market Share, by Application, 2025 (%) |
FIGURE 8 Global Oligonucleotide Synthesis Market Share, by End-User, 2025 (%) |
FIGURE 9 Global Oligonucleotide Synthesis Market Share, by Region, 2025 (%) |
FIGURE 10 North America Oligonucleotide Synthesis Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 11 Europe Oligonucleotide Synthesis Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 12 Asia-Pacific Oligonucleotide Synthesis Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 13 South America Oligonucleotide Synthesis Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 14 Middle East & Africa Oligonucleotide Synthesis Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 15 Competitive Landscape — Oligonucleotide Synthesis Market Revenue Share, 2025 (%)

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Product Type	Services; Synthesized Oligonucleotide Products; Reagents & Consumables	Services (~38% share, 2025)	Synthesized Oligonucleotide Products
By Chemistry	DNA; RNA; Modified Chemistries (LNA, PNA, etc.)	DNA (~40% share, 2025)	RNA
By Application	Research; Therapeutics; Diagnostics	Research (~49% share, 2025)	Therapeutics
By End-User	Academic Research Institutes; Pharmaceutical & Biotechnology Companies; Diagnostic Companies	Academic Research Institutes (~68% volume, 2025)	Pharmaceutical & Biotechnology Companies
By Geography	North America; Europe; Asia-Pacific; South America; Middle East & Africa	North America (~39% share, 2025)	Asia-Pacific

Market Segmentation Overview

By Product Type

Sub-Segment	Key Trend
Services	Pharma outsourcing to CDMOs drives sustained demand for GMP-certified contract synthesis
Synthesized Oligonucleotide Products	Therapeutic-grade, ready-to-use oligos replace in-house synthesis at smaller institutions
Reagents & Consumables	Phosphoramidite reagent demand stabilizes while enzymatic kits gain traction

The product type segmentation reflects a market in transition — services remain the revenue anchor, but the shift toward direct purchase of synthesized products is accelerating as quality standards and catalog breadth improve across leading suppliers.

By Chemistry

Sub-Segment	Key Trend
DNA	PCR primer and NGS adapter volumes sustain the largest share
RNA	mRNA therapeutics and CRISPR guide RNA applications drive the fastest growth
Modified Chemistries (LNA, PNA, etc.)	Demand tied to antisense and siRNA drug stability requirements

Chemistry segmentation captures the evolving balance between legacy DNA-centric demand and the rapid rise of RNA-based applications driven by therapeutic and gene-editing pipelines.

By Application

Sub-Segment	Key Trend
Research	High-volume, low-price academic orders dominate by unit count
Therapeutics	Premium pricing and GMP requirements drive disproportionate revenue growth
Diagnostics	Molecular testing expansion post-pandemic sustains steady demand for probes and primers

Application segmentation highlights the growing revenue importance of therapeutics, which command 15–20× the per-base pricing of research-grade oligos despite lower unit volumes.

By End-User

Sub-Segment	Key Trend
Academic Research Institutes	Largest customer base by order volume, funded primarily through government grants
Pharmaceutical & Biotechnology Companies	Highest value per customer through multi-year CDMO contracts
Diagnostic Companies	Growing demand for kit-grade probes and primers in companion diagnostics

End-user segmentation underscores the divergence between volume-driven academic demand and value-driven pharmaceutical procurement that increasingly defines competitive positioning in the market.

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”